European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination

Papillomavirus Research

Volumn 1, Issue , 2015, Pages 22-31

  von Karsa, Lawrence ^a   Arbyn, Marc ^b   De Vuyst, Hugo ^a   Dillner, Joakim ^c   Dillner, Lena ^d   Franceschi, Silvia ^a   Patnick, Julietta ^e   Ronco, Guglielmo ^f   Segnan, Nereo ^f   Suonio, Eero ^a   Törnberg, Sven ^g   Anttila, Ahti ^h  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^g Stockholm Regional Cancer Centre   (Sweden)

^h FINNISH CANCER REGISTRY   (Finland)

Author keywords

Cervical neoplasms; Evidence based guidelines; Human papillomavirus; Mass screening; Population based programme; Vaccination

Indexed keywords

WART VIRUS VACCINE;

CANCER PREVENTION; CANCER SCREENING; CYTOLOGY; DISEASE ASSOCIATION; EUROPE; HUMAN; INFECTION PREVENTION; INTERMETHOD COMPARISON; NONHUMAN; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS IDENTIFICATION; WART VIRUS;

EID: 84948151847     PISSN: None     EISSN: 24058521     Source Type: Journal    
DOI: 10.1016/j.pvr.2015.06.006     Document Type: Review

References (49)

1. Anttila A., Kotaniemi-Talonen L., Leinonen M., Hakama M., Laurila P., Tarkkanen J., Malila N., Nieminen P. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010, 340:c1804. 10.1136/bmj.c1804.
2. Anttila A., Ronco G., Nicula F., Nieminen P., Primic Žakelj M. Organization of cytology-based or HPV-based cervical cancer screening. S2. European Guidelines for Quality Assurance in Cervical Cancer Screening 2015, Office for Official Publications of the European Union, Luxembourg, (in press). second edition, Supplements. A. Anttila, A. Arbyn, H. De Vuyst, J. Dillner, L. Dillner, S. Franceschi, J. Patnick, G. Ronco, N. Segnan, E. Suonio, S. Törnberg, L. von Karsa (Eds.).
3. Anttila A., Lönnberg S., Ponti A., Suonio E., Villain P., Coebergh J.W., von Karsa L. Towards better implementation of cancer screening in Europe through improved monitoring and evaluation and greater engagement of cancer registries. Eur. J. Cancer 2015, 51:241-251.
4. European Guidelines for Quality Assurance in Cervical Cancer Screening 2008, European Commission, Office for Official Publications of the European Communities, Luxembourg. second edition. M. Arbyn, A. Anttila, J. Jordan, U. Schenck, G. Ronco, N. Segnan, H. Wiener, A. Herbert, J. Daniel, L. von Karsa (Eds.).
5. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N., Wiener H., Herbert A., von Karsa L. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann. Oncol. 2010, 21(3):448-458.
6. Arbyn M., Ronco G., Anttila A., Meijer C.J.L.M., Poljak M., Ogilvie G., Koliopoulos G., Naucler P., Sankaranarayanan R., Peto J. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine 2012, 30(Suppl. 5):F88-F99.
7. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Benbrahim-Tallaa L., Guha N., Freeman C., Galichet L., Cogliano V. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009, 10(4):321-322.
8. Bulkmans N.W., Rozendaal L., Snijders P.J., Voorhorst F.J., Boeke A.J., Zandwijken G.R., van Kemenade F.J., Verheijen R.H., Groningen K., Boon M.E., Keuning H.J., van Ballegooijen M., van den Brule A.J., Meijer C.J. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int. J. Cancer 2004, 110(1):94-101.
9. Commission of the European Communities, Report from the Commission to the Council, the European Parliament, the European Economic and Social committee and the Committee of the Regions - Implementation of the Council Recommendation of 2 December 2003 on cancer screening (2003/878/EC) Brussels, COM (2008) 882 final. Brussels: Commission of the European Communities, 2008. 26. Council of the European Union.
10. Council of the European Union Council recommendation of 2 December 2003 on cancer screening. Off. J. Eur. Union 2003, L 327:34-38. (2003/878/EC).
11. De Vuyst H., Howell-Jones R., Levy-Bruhl D., Giorgi Rossi P., Franceschi S. Implementation of vaccination against human papillomavirus in Europe. S3. European Guidelines for Quality Assurance in Cervical Cancer Screening 2015, Office for Official Publications of the European Union, Luxembourg, (in press). second edition, Supplements. A. Anttila, M. Arbyn, H. De Vuyst, J. Dillner, L. Dillner, S. Franceschi, J. Patnick, G. Ronco, N. Segnan, E. Suonio, S. Törnberg, L. von Karsa (Eds.).
12. Dijkstra M.G., van Niekerk D., Rijkaart D.C., van Kemenade F.J., Heideman D.A., Snijders P.J., Meijer C.J., Berkhof J. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol. Biomark. Prev. 2014, 23(1):55-63.
13. European Centre for Disease Prevention and Control (ECDC), Introduction of HPV vaccines in EU countries-an update, Stockholm. Available from: , 2012 (accessed 10.04.2015). http://ecdc.europa.eu/en/publications/publications/20120905_gui_hpv_vaccine_update.pdf.
14. Elfström K.M., Arnheim-Dahlström L., von Karsa L., Dillner J. Cervical cancer screening in Europe: quality assurance and organization of programmes. Eur. J. Cancer 2015, 51:950-968.
15. European Medicines Agency (EMA), Cervarix. Procedural steps taken and scientific information after the authorisation. EMA/620356/2012. Available from: , 2014a (accessed 10.04.2015). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000721/WC500024639.pdf.
16. European Medicines Agency (EMA), Gardasil. Procedural steps taken and scientific information after the authorisation. EMA/391688/2012. Available from: , 2014b (accessed 10.04.2015). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000703/WC500021147.pdf.
17. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49(6):1374-1403.
18. T. Greenhalgh, Why read papers at all? In: How to Read a Paper: The Basics of evidence-Based Medicine, BMJ Publishing Group, London, 1997, pp. 1-14.
19. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B: A Review of Human Carcinogens: Biological Agents 2012, International Agency for Research on Cancer, Lyon.
20. Kitchener H.C., Almonte M., Wheeler P., Desai M., Gilham C., Bailey A., Sargent A., Peto J. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br. J. Cancer 2006, 95(1):56-61.
21. Kitchener H.C., Gilham C., Sargent A., Bailey A., Albrow R., Roberts C., Desai M., Mather J., Turner A., Moss S., Peto J. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur. J. Cancer 2011, 47(6):864-871.
22. Kotaniemi-Talonen L., Nieminen P., Anttila A., Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br. J. Cancer 2005, 93(8):862-867.
23. Leinonen M., Nieminen P., Kotaniemi-Talonen L., Malila N., Tarkkanen J., Laurila P., Anttila A. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl. Cancer Inst. 2009, 101(23):1612-1623.
24. Leinonen M.K., Nieminen P., Lönnberg S., Malila N., Hakama M., Pokhrel A., Laurila P., Tarkkanen J., Anttila A. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ 2012, 345:e7789. Epub 2012 Nov 29. 10.1136/bmj.e7789.
25. Lynge E., Törnberg S., von Karsa L., Segnan N., van Delden J.J.M. Determinants of successful implementation of population-based cancer screening programmes. Eur. J. Cancer 2012, 48:743-748.
26. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., Ratnam S., Coutlee F., Franco E.L. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 2007, 357(16):1579-1588.
27. Minozzi S., Armaroli P., Segnan N. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition - principles of evidence assessment and methods for reaching recommendations. Endoscopy 2012, 44:SE9-SE14.
28. Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Elfgren K., Rådberg T., Strander B., Johansson B., Forslund O., Hansson B.G., Rylander E., Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 2007, 357(16):1589-1597.
29. Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Elfgren K., Rådberg T., Strander B., Forslund O., Hansson B.G., Hagmar B., Johansson B., Rylander E., Dillner J. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl. Cancer Inst. 2009, 101(2):88-99.
30. O'Connor D., Green S., Higgins J.P.T. Defining the review question and developing criteria for including studies. Cochrane Handbook for Systematic Reviews of Interventions (Wiley Cochrane Series) 2008, Wiley-Blackwell, UK. J.P.T. Higgins, S. Green (Eds.).
31. Richardson W.S., Wilson M.C., Nishikawa, Hayward R.S. The well-built clinical question: a key to evidence-based decisions. ACP J. Club 1995, 123:A12-A13.
32. Rijkaart D.C., Berkhof J., Rozendaal L., van Kemenade F.J., Bulkmans N.W., Heideman D.A., Kenter G.G., Cuzick J., Snijders P.J., Meijer C.J. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012, 13(1):78-88.
33. Ronco G., Segnan N. HPV testing for primary cervical cancer screening. Lancet 2007, 370(9601):1740-1742.
34. Ronco G., Arbyn M., CJLM Meijer, Snijders P.J.F., Cuzick J. Screening for cervical cancer with primary testing for human papillomavirus. S1. European Guidelines for Quality Assurance in Cervical Cancer Screening 2015, Office for Official Publications of the European Union, Luxembourg, (in press). second edition, Supplements. A. Anttila, A. Arbyn, H. De Vuyst, J. Dillner, L. Dillner, S. Franceschi, J. Patnick, G. Ronco, N. Segnan, E. Suonio, S. Törnberg, L. von Karsa (Eds.).
35. Ronco G., Dillner J., Elfström K.M., Tunesi S., Snijders P.J., Arbyn M., Kitchener H., Segnan N., Gilham C., Giorgi-Rossi P., Berkhof J., Peto J., Meijer C.J. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014, 383(9916):524-532.
36. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., Ghiringhello B., Girlando S., Gillio-Tos A., De Marco L., Naldoni C., Pierotti P., Rizzolo R., Schincaglia P., Zorzi M., Zappa M., Segnan N., Cuzick J. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010, 11(3):249-257.
37. Ronco G., Giorgi-Rossi P., Carozzi F., Dalla Palma P., Del Mistro A., De Marco L., De Lillo M., Naldoni C., Pierotti P., Rizzolo R., Segnan N., Schincaglia P., Zorzi M., Confortini M., Cuzick J. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006, 7(7):547-555.
38. Ronco G., Segnan N., Giorgi-Rossi P., Zappa M., Casadei G.P., Carozzi F., Dalla Palma P., Del Mistro A., Folicaldi S., Gillio-Tos A., Nardo G., Naldoni C., Schincaglia P., Zorzi M., Confortini M., Cuzick J. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. Natl.Cancer Inst. 2006, 98(11):765-774.
39. Sankaranarayanan R., Nene B.M., Dinshaw K.A., Mahe C., Jayant K., Shastri S.S., Malvi S.G., Chinoy R., Kelkar R., Budukh A.M., Keskar V., Rajeshwarker R., Muwonge R., Kane S., Parkin D.M., Chauhan M.K., Desai S., Fontaniere B., Frappart L., Kothari A., Lucas E., Panse N. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int. J. Cancer 2005, 116(4):617-623.
40. Sankaranarayanan R., Nene B.M., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., Hingmire S., Malvi S.G., Thorat R., Kothari A., Chinoy R., Kelkar R., Kane S., Desai S., Keskar V.R., Rajeshwarkar R., Panse N., Dinshaw K.A. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 2009, 360(14):1385-1394.
41. N. Segnan, J. Patnick, L. von Karsa, (Eds.), European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis, in: first edition, European Commission, Office for Official Publications of the European Union, Luxembourg, 2010.
42. von Karsa L., Anttila A., Ronco G., Ponti A., Malila N., Arbyn M., et al. Cancer Screening in the European Union. Report on the implementation of the Council Recommendation on Cancer Screening-First Report 2008, European Commission, Luxembourg.
43. von Karsa L., Anttila A., Primic Žakelj M., de Wolf C., Bielska-Lasota M., Törnberg S., Segnan N. Stockholm statement on successful implementation of population-based cancer screening programmes. Annex 1a. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis 2013, 123-128. European Commission, Office for Official Publications of the European Union, Luxembourg. fourth edition, Supplements. N. Perry, M. Broeders, C. de Wolf, S. Törnberg, R. Holland, L. von Karsa (Eds.).
44. von Karsa L., Patnick J., Segnan N., European Colorectal Cancer Screening Guidelines Working Group, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013, 45:51-59.
45. von Karsa L., Qiao Y.-L., Ramadas K., Keita N., Arrossi S., Dean P.B., Al Alwan N., Sankaranarayanan R. Screening-implementation, Chapter 4.8. World Cancer Report 2014 2014, 330-336. International Agency for Research on Cancer, Lyon. B.W. Stewart, C.P. Wild (Eds.).
46. WHO Global advisory committee on vaccine safety, report of meeting held 17-18 June 2009. Wkly. Epidemiol. Rec. 2009, 84(32):325-332.
47. WHO Human papillomavirus vaccines. WHO position paper. Wkly. Epidemiol. Rec. 2009, 84(15):118-131.
48. WHO Global advisory committee on vaccine safety, report of meeting held 11-12 December 2013. Wkly. Epidemiol. Rec. 2014, 89(7):53-60.
49. WHO Human papillomavirus vaccines: WHO position paper, October 2014. Wkly. Epidemiol. Rec. 2014, 89(43):465-491.